P ainful diabetic neuropathy (PDN) is one of the most common causes of chronic pain in patients with diabetes; approximately 30% of patients with diabetes have pain related to PDN. 1, 2 The primary clinical manifestation of PDN is mechanical hypersensitivity, [3] [4] [5] similar to neuropathic pain related to nerve injury. Painful diabetic neuropathy can significantly affect the patient's quality of life. [6] [7] [8] Thus, the management of PDN is crucial in the care of patients with diabetes.
Current evidence suggests chronic hyperglycemia, microvascular insufficiency and neural inflammation related to diabetes are primary factors in the development of PDN. 5 Chronic hyperglycemia disrupts homeostasis in the nervous system, increases metabolic stress and produces various by-products that affect the function of the vascular system. The most notable example is advanced glycation end products. 5, 9, 10 The accumulation of advanced glycation end products on the vascular wall can result in vascular insufficiency and disrupt the supply of oxygen, nutrient and the removal of waste in surrounding tissue, eventually develops ischemic damage. Areas that rely primarily on small vessels, such as peripheral nerves are particularly susceptible to ischemic damage in this situation. Thus peripheral nerves are one of the first areas that were affected by vascular insufficiency in patients with diabetes. 5, 9, 10 The concentrations of proinflammatory mediators, such as tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β), increase in the nerves after ischemic damage and lead to the sensitization of local nerve endings and the development of symptoms, including mechanical hypersensitivity. 5, 9, 10 In addition to changes in the peripheral nervous system, changes in dorsal root ganglion and spinal cord dorsal horn are also involved in the development of neuropathic pain, in the form of central sensitization. 4, 5, 11, 12 However, the physiological mechanism of central sensitization is still unclear. Current understanding of the pathological mechanism of PDN suggests that ischemic nerve damage and ensuing inflammation in the peripheral nervous system are the primary factors in the development of PDN. However, central sensitization is still a factor that needs to be taken into consideration.
Most clinical management for PDN is only for alleviating the symptom. Currently, the first-line medication for PDN is pregabalin. 13 However, pregabalin is known for having unpleasant side effects, and its use is limited in certain types of patients, such as patients with renal dysfunction or patients who are pregnant. In addition to pharmacological intervention, nonpharmacological options such as physical exercise are also being studied to develop better options for the management of PDN. 14 Because ischemic nerve damage and ensuing inflammation play a crucial part in the development of PDN, another intervention that was effective in managing pain related to ischemic nerve damage may also be effective in managing pain related to PDN. Neural mobilization is a technique commonly used to manage pain caused by ischemic nerve damage. The basic concept is to mobilize the nerve through specific movements. By mobilizing the nerve it creates tension change in the nerve and produces pumping effect 15 that facilitates fluid dispersion in the nerve tissue to restore homeostasis. 16, 17 In theory, it is likely to improve circulation in the nerve and alleviate inflammation caused by ischemic damage. Although the basic concept and current research suggest that neural mobilization has the potential for managing PDN, 18, 19 direct evidence of its effect on PDN is still lacking. Also, the risk of inflicting further nerve damage in patients with PDN still exists, as a previous study indicated. 20 In order to evaluate the potential and risk, direct studies of the treatment effect and physiological mechanism of neural mobilization in animal models are needed.
The purpose of this study was to evaluate the treatment effect of neural mobilization and investigate the physiological mechanism of neural mobilization in the control of pain related to PDN using a streptozocin (or streptozotocin; STZ)-induced type 1 diabetic rat model. We assessed mechanical sensitivity and the concentrations of proinflammatory mediators TNF-α and IL-1β in the sciatic nerve trunk and sciatic nerve branches, dorsal root ganglion, and spinal cord dorsal horn to evaluate the effect of neural mobilization in managing mechanical allodynia related to PDN and to investigate its relationship with the concentrations of proinflammatory cytokines in the nervous system.
Methods

Animals and Experiment Model
Mature male Sprague-Dawley rats weighing 300 to 320 g (National Cheng Kung University Animal Center) were used. Three groups each consisted of 6 rats. Animals were housed at a constant room temperature (25°C ± 2°C) and had access to free food and water throughout the study. Experiment protocols were approved by the Institutional Animal Care and Use Committee of National Cheng Kung University, Tainan, Taiwan (Republic of China). An STZ-induced type 1 diabetes model was used. The rats were fasted for 72 hours prior to injection according to an established experiment protocol. 14 On the day of induction, rats were anesthetized with intraperitoneal pentobarbital (Sigma-Aldrich Co, St Louis, Missouri) injection (35 mg/kg), and STZ (Sigma-Aldrich Co) was injected into the femoral vein (65 mg/kg). Rats in the vehicle group underwent the same procedure but were injected with normal saline. Confirmation of diabetes took place 3 days after STZ injection; rats with a fasting (8-hour) blood glucose level (Accu-Check Active blood glucose testing set; Roche Boehringer Mannheim Diagnostics, Mannheim, Germany) of greater than 300 mg/dL were considered to have successfully induced type 1 diabetes.
Behavior Tests
Behavior tests include a baseline test and a daily behavior test (Fig. 1) . All rats underwent adaptation for 3 days prior to the baseline test. After adaptation, all rats received a baseline test, and from days 3 to 7 after STZ injection, all rats received a 1-week behavior test to confirm the development of PDN. Diabetic rats with a decreased mechanical response threshold compared to the baseline were considered to have successfully developed PDN. After confirmation, rats with PDN were randomly allocated to the diabetes group (PDN group) and the neural mobilization treatment group (PDN-NM group). In the course of the study, all rats received a behavior test once per day, whereas rats in the PDN-NM group received daily neural mobilization in addition to the behavior test. The behavior test in the PDN-NM group was conducted 2 hours after treatment to ensure that the animal was fully recovered from anesthesia.
The von Frey test was used to test mechanical pain sensitivity. Monofilaments (Touch-Test, Fabrication Enterprises Inc, White Plains, New York) with intensities from 0.2 to 26 g were used to stimulate the rat's paw. Each stimulus lasted for 5 seconds. If the rat had a withdraw respond within the 5-second window, a retest would be taken to confirm the response. The stimulus intensity was recorded as the response threshold. Each rat was tested twice, and the 2 response thresholds were averaged.
Neural Mobilization
The neural mobilization protocol was modeled after that used in the studies of Santos et al. 21, 22 The principle is to mobilize the sciatic nerve by putting the nerve in maximum elongation, and apply extra tension through ankle oscillation. The rats were anesthetized with 3% isoflurane gas, and positioned in a side-lying position with hip fixed at 70 to 80 degrees of flexion, knee at full extension. Neural mobilization was applied by oscillating the ankle in dorsiflexion/plantar flexion pattern. The range of ankle dorsiflexion was 20 to 25 degrees from neutral, the ankle was dorsiflexed to the point which first resistance was felt to mobilize the sciatic nerve without overstretching it. The detailed treatment protocol is shown in the Table. Rats in the PDN-NM group received neural mobilization treatment from day 10 after STZ injection (Fig. 1) ; the rats received 5 treatment sessions per week for 3 weeks.
Sample Collection, Preparation, and Cytokine Assay
In the end of the experiment, rats were sacrificed for sample collection. Rats underwent deep anesthesia via intraperitoneal urethane (Sigma-Aldrich Co) injection (1.4 g/kg) and were transcardially perfused with normal saline. Samples of the sciatic nerve trunk, sciatic nerve branches (including tibial, peroneal, and sural nerves), L4 to L6 dorsal root ganglion, and L4 to L6 spinal cord dorsal horn were collected. Separation of the spinal cord dorsal horn was done according to the anatomical structure of the laboratory rat. 23 First, a whole section of L4 to L6 spinal cord was removed and divided in half by the posterior median sulcus. After separation of the left and right, the upper half of each half was collected. All samples were cleaned in normal saline and stored in a liquid nitrogen tank immediately after extraction.
Sample preparation. Samples of nerves, dorsal root ganglion, and spinal cord dorsal horn were homogenized in tissue protein extraction reagent (T-PER; ThermoFisher Scientific, Waltham, Massachusetts) mixed with protease inhibitor (Complete Protease Inhibitor Cocktail Tablets; Hoffman-Roche, Basel, Switzerland). After homogenization, samples were incubated on ice for 1 hour and centrifuged in a high-speed centrifuge machine. The supernatant of the centrifuged samples was immediately collected and stored in a freezer at −80°C.
Protein quantification. A protein quantification assay was performed with a bicinchoninic acid protein assay kit (Cat. No. 23227; Thermo Scientific). The testing procedure was performed according to the instruction manual. Optical density was measured in a plate reader with a 595-nm filter. The protein concentration was calculated using software developed by Ascent Software (London, United Kingdom).
Cytokine assay. The concentrations of TNF-α and IL-1β were measured with a DuoSet ELISA Development Kit (R&D Systems, Minneapolis, Minnesota). The testing procedure was performed according to the instructions in the manual for the kit. Optical density was measured in a plate reader with a 450-nm filter Cytokine concentrations were calculated with Ascent Software. Data generated from the ELISA test were normalized with the protein concentration in each sample.
Statistical Analysis
The behavior data from baseline to 28 days after STZ injection were analyzed with 2-way repeated-measures analysis of variance followed by a post hoc least significant difference test. In addition, we compared single time point data from baseline, day 7 after STZ injection (before neural mobilization treatment), and days 14, 21, and 28 after STZ injection (the last day of the first, second, and third weeks after the initiation of treatment) with a 1-way analysis of variance followed by a post hoc least significant difference test to investigate differences at different times. We also used a paired t test to compare the behavior data of the same group before and after STZ injection to investigate the change in the response threshold before and after the development of PDN; the same analysis was also used to compare the behavior data from day 7 after STZ injection and days 14, 21, and 28 after STZ injection to show the change in the response threshold after treatment.
The results of the cytokine assay were analyzed with a 1-way analysis of Timetable of the experimental procedure. DM = diabetes mellitus, STZ = streptozocin.
variance followed by a post hoc least significant difference test to compare the cytokine concentrations in different groups. A paired t test analysis was also used to compare the concentrations of cytokines in the nerve between treated and nontreated sides in each group. Statistical analysis was performed with SPSS 17.0 (IBM SPSS; IBM Corp, Armonk, New York), and significance was set at a P value of less than .05. 
Role of the Funding Source
Results
PDN Causes a Significant Decrease in the Mechanical Response Threshold
The mechanical response threshold of diabetic rats was significantly decreased after STZ injection. The response threshold of both left and right paws on day 7 after STZ injection was significantly lower compared to the baseline in the PDN and PDN-NM groups (Fig. 2) . Compared with the rats in the vehicle group, diabetic rats in the PDN group had significantly lower response thresholds on both sides (P < .0001); the reduction in the response threshold was present throughout the experiment (Fig. 2A) . The same findings were also found in the PDN-NM group on the left (nontreated) side (Fig. 2A) . These findings indicated that the animals with PDN developed severe mechanical hypersensitivity after the induction of type 1 diabetes, and it persisted throughout the study.
Neural Mobilization Alleviates Mechanical Hypersensitivity on the Treatment Side
The rats in the PDN-NM group had a significantly higher response threshold on the right (treated) side than those in the PDN group (P < .0001) (Fig. 2B) . We also compared the right (treated) side data from all 3 groups at different times (days 7, 14, 21, and 28 after STZ injection) and found that the response threshold of the PDN-NM group on day 7 after STZ injection (pretreatment) was on par with that of the PDN group, but the data on days 14, 21, and 28 after STZ injection were all significantly higher in the PDN-NM group than in the PDN group (all P < .0001) (Fig. 2B) . In addition, the response threshold on the right (treated) side of the PDN-NM group was significantly lower on day 7 after STZ injection (pretreatment) than on days 14, 21, and 28 after STZ injection (posttreatment) (Fig. 2B) , indicating that mechanical allodynia was significantly alleviated after treatment.
On the left (nontreated) side, however, there was no significant difference between the response threshold of the PDN group and that of the PDN-NM group (P = .391), indicating that the effect of neural mobilization was limited to the treatment side.
Rats in the PDN Group Had Higher Concentrations of IL-1β But Not TNF-α in the Sciatic Nerve Branches and Sciatic Nerve Trunk
The concentration of IL-1β was significantly higher in both left and right sciatic nerve branches and sciatic nerve trunk of rats in the PDN group (P = .001 and .024 for the left and right sciatic nerve branches, respectively; P = .048 and .022 for the left and right sciatic nerve trunk, respectively) than in the vehicle group (Figs. 3A and 3B) . However, there was no significant difference in the concentration of TNF-α between groups in both left and right sciatic nerve branches and sciatic nerve trunk (Figs. 3C and 3D) .
Rats in the PDN-MN Group Had Lower Concentrations of Both IL-1β and TNF-α in the Sciatic Nerve Branches and Sciatic Nerve Trunk on the Treatment Side
The concentration of IL-1β in the right (treated) sciatic nerve branches and sciatic nerve trunk in the PDN-NM group was not significantly higher than that in the vehicle group (P = .259 and .144 in the right sciatic nerve branches and trunk, respectively); in contrast, the concentration of IL-1β in the PDN group was significantly higher than that in the vehicle group (P = .024 and .022 in the right sciatic nerve branches and trunk, respectively). However, there also was no significant difference between the PDN and PDN-NM groups (P = .203 and .325 in the right sciatic nerve branches and trunk, respectively). When the concentrations of IL-1β in the left (nontreated) and right (treated) sciatic nerve branches and sciatic nerve trunk were compared, that on the right side was significantly lower than that on the left side (Figs. 3A and 3B) (P = .023 for sciatic nerve branches; .026 for sciatic nerve trunk). These findings suggest that the concentration of IL-1β in the sciatic nerve branches and sciatic nerve trunk in the PDN-NM group was significantly lower on the treated side than on the nontreated side.
Although there was no difference in the concentration of TNF-α in the sciatic nerve branches and sciatic nerve trunk between groups, the concentration of TNF-α in the right (treated) sciatic nerve branches and sciatic nerve trunk in the PDN-NM group was significantly lower than that on the left (nontreated) side (Figs. 3C and 3D) (P = .004 for sciatic nerve branches; .012 for sciatic nerve trunk), similar to the findings in the IL-1β assay.
The results showed that the right (treated) sciatic nerve branch and sciatic nerve trunk that received neural mobilization had lower concentrations of both IL-1β and TNF-α than the left side, indicating that neural mobilization may be able to decrease the concentrations of proinflammatory cytokines in nerve tissue and thus affect the sensitivity of the nerve.
Although the difference in the concentration of IL-1β in between the PDN and PDN-NM groups was not statistically significant, the mean IL-1β concentration in the right (treated) sciatic nerve branches and sciatic nerve trunk in the PDN-NM group was consistently lower than those in the PDN group, suggesting that the reduction in the IL-1β concentration may still contribute to the alleviation of symptoms.
No Significant Differences in Cytokine Concentrations in the Dorsal Root Ganglion and Spinal Cord Dorsal Horn Between Groups
We also measured the concentrations of TNF-α and IL-1β in the L4 to L6 dorsal root ganglion and spinal cord dorsal horn. The results showed that there was no significant difference between groups. A comparison of the concentrations of TNF-α and IL-1β in the left and right dorsal root ganglion and spinal cord dorsal horn also showed no significant difference (Fig. 4) .
Discussion Neural Mobilization Attenuates Mechanical Allodynia in Rats With PDN
Clinically, pain caused by PDN is manifested through various symptoms, including mechanical hypersensitivity, thermal hypersensitivity, and spontaneous pain. 5, 12, 24, 25 However, clinical manifestations vary between individuals. For instance, thermal hypersensitivity is not always present and probably develops independently from mechanical hypersensitivity. 26, 27 However, most studies suggested that mechanical hypersensitivity is consistently present. 3, 12, 14, 28, 29 Our results showed that all rats with PDN developed mechanical allodynia and that it was effectively alleviated after neural mobilization treatment. However, the effect was shown only on the treated side. These findings suggest that neural mobilization was effective in attenuating mechanical allodynia, but the effect was limited to the treated area.
We did not observe any signs of neural injury, such as limping or muscle atrophy, in the rats that received neural mobilization. However, a more in-depth assessment of motor function and a histological assessment are needed to determine whether there was any negative effect on the rats.
Decreased Concentrations of Proinflammatory Mediators in the Sciatic Nerve Branches and Sciatic Nerve Trunk May Be Relate to Decreased Mechanical Sensitivity
Our results showed that rats in the PDN-NM group had lower concentrations of both IL-1β and TNF-α in the right (treated) sciatic nerve branches The PDN-NM group showed a significant increase in the response threshold after receiving treatment. When single time points on days 7, 14, 21, and 28 were compared, the response threshold of the PDN-NM group was significantly higher than that of the PDN group on days 14, 21, and 28 (after receiving neural mobilization treatment). Two-way repeated-measures analysis of variance followed by a post hoc least significant difference (LSD) test revealed the following results: * P < .05 compared to the vehicle group (data from baseline to day 28 after STZ injection); + P < .05 compared to the PDN group (data from baseline to day 28 after STZ injection). One-way analysis of variance followed by a post hoc LSD test revealed the following result: # P < .05 compared to the PDN group (data from a single time point). Analysis with a paired t test revealed the following results: @ P < .05 compared to data from day 7 (pretreatment) for each group (data from a single time point); % P < .05 compared to data from the baseline for each group (data from a single time point).
and sciatic nerve trunk than on the left (nontreated) side. This finding is consistent with the results of the behavior test, which showed a reduction in mechanical sensitivity of the right but not the left paw.
When we compared the concentrations of proinflammatory cytokines between groups, we found that the concentration of IL-1β was significantly higher in both left and right sciatic nerve branches and sciatic nerve trunk in the PDN group than in the vehicle group, whereas only the left (nontreated) side in the PDN-NM group had a significantly higher IL-1β concentration than the vehicle group. The IL-1β concentration in the right (treated) sciatic nerve branch and sciatic nerve trunk in the PDN-NM group was not significantly different from that in either the vehicle group or the PDN group. On the other hand, there was no significant difference in the concentration of TNF-α in the sciatic nerve branches and sciatic nerve trunk in the 3 groups, unlike the results shown in the IL-1β assay. This finding indicates that in our particular setting (4 weeks after the induction of diabetes), the TNF-α concentration in the peripheral nerve system may not have contributed as much as the IL-1β concentration to the severity of mechanical allodynia. However, TNF-α is widely known as a sensitizing agent in various types of neuropathic pain, includingPDN, [30] [31] [32] [33] but its expression in the nervous system may also vary in different phases of the disease. 34 This notion requires further study to investigate.
The proinflammatory cytokines TNF-α and IL-1β are known to be involved in the development of mechanical and thermal hypersensitivity in neuropathic pain. 24, 33, [35] [36] [37] The functions of these cytokines are primarily the initiation and maintenance of inflammation. However, they can also sensitize nerve endings or The concentration of IL-1β was significantly higher in the left sciatic nerve branches and sciatic nerve trunk of both PDN and PDN-NM groups, whereas on the right side, only the PDN group had a significantly higher concentration than the vehicle group. The data are presented as the mean ± standard error of the mean for 6 assays per group. Oneway analysis of variance for repeated measures followed by a post hoc least significant difference (LSD) test revealed the following result: * P < .05 compared to vehicle group for the same side (left or right). The concentrations of TNF-α and IL-1β were significantly lower on the right side in the PDN-NM group, whereas the PDN and vehicle groups showed no significant differences between the left and the right sides. The data are presented as the mean ± standard error of the mean for 6 assays per group. Analysis with a paired t test revealed the following result: + P < .05 compared to the left (nontreated) side in the respective group.
produce peripheral sensitization via a second messenger pathway. 34 However, the roles of TNF-α and IL-1β in nerve inflammation are quite different. TNF-α is more of an "initiator" in the process; it initiates a cascade of the production of several cytokines, including IL-1β, IL-6, and IL-8. 34 The cascade eventually leads to the release of prostanoid by activating cyclooxygenase-2. 38 On the other hand, IL-1β is more involved in chronic inflammation, such as rheumatoid arthritis. 1, 39 The respective roles of TNF-α and IL-1β in neural inflammation in PDN are still unclear. Previous studies indicated that TNF-α and IL-1β may be involved in different phases of the process of neuropathy, 34 but further study is still needed to investigate the changes in TNF-α and IL-1β expression at different times.
Overall, our findings indicated that part of the physiological mechanism of the treatment effect of neural mobilization may be related to the altered concentrations of proinflammatory cytokines in the peripheral nervous system. In addition, IL-1β and TNF-α may play different roles in the maintenance of hypersensitivity in different stages of PDN. This notion suggests new research directions, such as the roles of different cytokines and histological changes in different phases of neuropathy.
Limited Involvement of the Concentrations of Proinflammatory Cytokines in the Dorsal Root Ganglion and Spinal Cord Dorsal Horn in the Treatment Effect of Neural Mobilization
A previous study indicated that rats with type II diabetes and PDN have increased expression of multiple proinflammatory cytokines, including TNF-α and IL-1β, in the dorsal root ganglion. 31 However, we did not see the same side. There were no significant differences between the groups, nor were there significant differences in the concentrations of both IL-1β and TNF-α between the treated side and the nontreated side.
phenomenon in the type 1 diabetic rats used in the present study. The pathophysiology of pain development in PDN at the level of the dorsal root and central nervous system is still unclear, but the difference could come from the use of different animal models 40 or different time periods. However, in the present study, the involvement of the concentrations of proinflammatory mediators in the dorsal horn ganglion and spinal cord dorsal horn may have been limited, as the results suggested.
Study Limitations
In the present study, we did not measure the nerve blood flow in the sciatic nerve because the focus of the study was the effect of neural mobilization on pain and inflammation in nerve tissue related to PDN. Our results did show a strong desensitizing effect provided by neural mobilization and significant differences in the concentrations of IL-1β and TNF-α between the nerve that received treatment and those that did not in the same group. These results suggested that the changes in the concentrations of proinflammatory cytokines were likely related to the changes in symptoms. However, future study directly measuring nerve blood flow is still needed to explain how neural mobilization treatment changes the concentrations of proinflammatory cytokines in nerve tissue.
Conclusions
The present study showed that neural mobilization is effective in attenuating mechanical allodynia related to PDN in rats. This finding indicates the high effectiveness of neural mobilization in controlling the mechanical hypersensitivity commonly manifested in patients and animals with PDN. Although no significant signs of neural injury were observed in rats in the PDN-NM group, further histological and motor function tests are still needed to determine whether neural mobilization has other negative effects on animals with PDN.
The other important information from the present study is that the mechanism behind the treatment effect of neural mobilization may be related to the reduction in the concentrations of proinflammatory mediators in the peripheral nervous system. Although neural mobilization is widely used for neuropathic pain management, the underlying physiological mechanism is still largely unknown. The present study provides insight into the physiological mechanism involved in the effect of neural mobilization. However, in order to fully explain the physiological mechanism of the treatment effect of neural mobilization, further study is needed. We plan to perform studies to investigate other aspects of the physiological mechanism, such as the effect on nerve blood flow, in order to provide more evidence to support the use of neural mobilization in clinics.
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